Factorial Biotechnologies

Executive Summary

Factorial Biotechnologies is a Cambridge, MA-based biotech pioneering high-throughput protein engineering for therapeutic antibody discovery. Founded in 2017, the company leverages proprietary synthetic biology and screening platforms to generate and analyze vast antibody variant libraries, identifying candidates with superior properties for diagnostics and therapeutics. While specific funding and valuation remain undisclosed, Factorial's focus on accelerating antibody development positions it in a competitive but high-demand sector. The company's platform-based approach enables partnerships and out-licensing, though commercial traction is unconfirmed. Future success hinges on securing strategic collaborations and demonstrating platform validation through preclinical or clinical milestones.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round Completion60% success
• H1 2027Major Pharma Partnership for Antibody Discovery40% success
• Q2 2026Publication of Platform Validation in Peer-Reviewed Journal50% success